David Gómez Andrés - Institutions of which they are part Head of group Therapeutics and Innovations in Neuropediatrics and other paediatric rare diseases Vall Hebron Institut de Recerca Doctor Paediatric Neurology Children's Hospital and Woman's Hospital Twitter Email David Gómez Andrés Twitter Email Institutions of which they are part Head of group Therapeutics and Innovations in Neuropediatrics and other paediatric rare diseases Vall Hebron Institut de Recerca Doctor Paediatric Neurology Children's Hospital and Woman's Hospital -
Research lines Gene Therapy for the Treatment of Congenital Muscular Dystrophy Due to Merosin Deficiency Development of a new gene therapy strategy based on high-capacity adenoviral vectors, in collaboration with the Gene and Cell Therapy group at VHIR, led by Dr. Jordi Barquinero and Dr. María Pallarès-Masmitjà. IP: David Gómez Andrés Imaging Biomarker Study in Neuropediatric Diseases The application of advanced magnetic resonance imaging (MRI) techniques enables an objective and quantitative characterization of the progression of various neurological diseases. This research focuses on developing imaging biomarkers to identify radiological patterns. For neuromuscular diseases, the aim is to identify specific patterns of fat replacement and muscle inflammation, as well as to correlate these changes with motor function and other clinical parameters. For patients with movement disorders, specific imaging patterns will be studied to establish efficacy biomarkers for deep brain stimulation. This will contribute to better patient stratification and evaluation of responses to different experimental treatments. IP: Belen Perez Dueñas, David Gómez Andrés Digital Biomarker Study in Neuropediatric Diseases Digital tools provide a unique opportunity to continuously and objectively monitor pediatric patients with neurological disorders. This project aims to identify and validate digital biomarkers using wearable sensors, video analysis, movement pattern analysis, and artificial intelligence applied to clinical data. The ultimate goal is to improve diagnosis, monitoring, and personalized treatment for children with complex neurological diseases. IP: David Gómez Andrés, Belen Perez Dueñas Pagination First page « Previous page ‹ Page 1 Page 2 Page 3 Page 4 Current page 5